Transmedics Group Inc (TMDX)

NASD · Healthcare · Medical Devices · USA

Transmedics Group Inc is a mid cap company (market value between $2 billion and $10 billion) in the Medical Devices industry.

Transmedics Group develops the OCS, a portable warm perfusion system for preserving donor hearts, lungs and livers outside the body during transplantation. The company also offers the National Organ Program, which provides organ procurement, perfusion management and transplant logistics services to transplant centers. Its products and services address end-stage organ failure patients worldwide.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Transmedics Group Inc stock.

Our verdict on TMDX

Fairly valued: intrinsic value $96.40 per share, market price $93.91, margin of safety 2.6% (as of 2026-11-17).

Discounting its cash flows at 12.1% (average of 2 methods) values the shares at $96.40; the price of $93.91 is 3% below that value.

ETFs with the most weight in TMDX

17 more funds hold it; the full list is part of the paid plan.

More on TMDX

Browse

Peers in Medical Devices

All 140 Medical Devices stocks

Cheaper than TMDX in Medical Devices

13 more in this industry show a wider margin of safety.

Is TMDX undervalued or overvalued?

TMDX is fairly valued (as of the 2026-11-17 close). Discounting its cash flows at 12.1% (average of 2 methods) values the shares at $96.40; the price of $93.91 is 3% below that value.

What is the intrinsic value of TMDX?

$96.40 per share (as of the 2026-11-17 close), against a market price of $93.91. That is a margin of safety of 2.6%. The value is the average of the 2 valuation methods that apply to this company, recomputed every night after the US close.